Twist Bioscience
TWST
204 hedge funds and large institutions have $2.01B invested in Twist Bioscience in 2022 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 84 increasing their positions, 49 reducing their positions, and 38 closing their positions.
152% more call options, than puts
Call options by funds: $7.38M | Put options by funds: $2.92M
71% more repeat investments, than reductions
Existing positions increased: 84 | Existing positions reduced: 49
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
3.01% less ownership
Funds ownership: 106.15% → 103.14% (-3%)
4% less funds holding
Funds holding: 212 → 204 (-8)
13% less first-time investments, than exits
New positions opened: 33 | Existing positions closed: 38
31% less capital invested
Capital invested by funds: $2.92B → $2.01B (-$914M)
Top Buyers
| 1 |
State Street
Boston,
Massachusetts
|
+$47.3M |
| 2 |
JP Morgan Chase
New York
|
+$38.9M |
| 3 |
William Blair Investment Management
Chicago,
Illinois
|
+$37M |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$35.5M |
| 5 |
Morgan Stanley
New York
|
+$21.6M |
Top Sellers
| 1 |
Capital World Investors
Los Angeles,
California
|
-$145M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$108M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$42.2M |
| 4 |
CC
Casdin Capital
New York
|
-$13.5M |
| 5 |
Goldman Sachs
New York
|
-$12.8M |
TWST Hedge Fund Activity: Q2 2022 in Review
204 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Twist Bioscience (TWST) for Q2 2022, worth a combined $2.01B — down 31% from $2.92B a quarter earlier.
Sellers outnumbered buyers: 38 funds closed out of TWST and 33 opened new positions — a net loss of 5 holders — while 49 trimmed existing stakes and 84 added.
The largest buyer was State Street, adding an estimated $47.3M. The largest seller was Capital World Investors, cutting an estimated $145M.
- 204 institutional investors held Twist Bioscience (TWST) as of Q2 2022, down from 212 in Q1 2022.
- Funds reported $2.01B of Twist Bioscience stock for Q2 2022, down 31% quarter-over-quarter.
- 33 funds opened new Twist Bioscience positions in Q2 2022 and 38 closed out, a net change of -5 holders.
- The largest Twist Bioscience buyer in Q2 2022 was State Street, an estimated $47.3M added.
- The largest Twist Bioscience seller in Q2 2022 was Capital World Investors, an estimated $145M sold.
Based on aggregated 13F filings for Q2 2022.